SAN DIEGO, CA--(Marketwired - April 10, 2013) - True Diagnostics, Inc.™ (www.TrueDiagnostics.com), a company dedicated to the discovery and development of innovative diagnostic solutions, announced today it has received Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its application covering quantitative testing method used for the TrueDX™ Platform. With this new technology, medical professionals and patients can now immediately perform multiple tests simultaneously using a finger-prick of blood -- rather than wait days for test results from an intravenous blood draw. The allowed patent, titled "Quantitative analyte assay device and method" has the earliest priority date of December 2008. The patent is expected to issue in the next few months. True Diagnostics retains an exclusive license to use, develop, and commercialize this patent.
This is the second Notice of Allowance covering the TrueDX™ Platform. The company also has separate pending international applications covering multiple regions worldwide.
Jerry Lee, President/CEO of True Diagnostics, notes, "We are pleased to reach a major benchmark in our vision to bring forward a generation of new tests. With our technology we can help apply this towards improving the way we diagnose, monitor and treat patients worldwide. We have the potential to increase testing specificity, reduce testing lead times, and simplify testing procedures using one diagnostic platform."
About the Company
For the $21 billion point-of-care market, the power of the TrueDX™ Platform lies in its simplicity: tests have a 24-month shelf life; they do not need refrigeration; and, laboratory quality results from small samples can now be available to doctors in minutes. The TrueDX™ Platform's simplicity, portability, and affordability also allow it to be easily adopted into emerging markets. The platform's flexible design additionally permits it to quickly commercialize a myriad of new biomarkers discoveries for cancer, autism, alzheimer's, diabetes, drugs of abuse, infectious diseases, cardiac health, traumatic brain injury, viral and bacterial infections, and more. In essence, any biomarker discovery utilizing traditional lab methods, such as an ELISA process, can now be developed into a simple, fast, and portable assay which can offer quick diagnosis and treatment at the point-of-care, point-of-incidence and remote-of-care settings.
For more information, call 760-683-9158 or go to www.TrueDiagnostics.com
